The company seeks to address patient-specific pathophysiology based on the patient’s genetic profile. The company has a relationship with Stanford Cardiovascular Institute with which they developed their discovery platform that can be used to develop genetically-targeted therapies while also addressing cardiotoxicity.
Divya Nag and fellow student Andrew Lee started Stem Cell Theranostics with their professors. Nag is no longer with Stem Cell Theranostics, and has started StartX Med, a medical arm of Standford Student Enterprises Labs and now works for Apple in the Health Special Projects section.
On January 1, 2014 Stem Cell Theranostics completed their series A funding round with $5.5 million in funding from Bill Marcus.
Joseph C. Wu M.D., Ph.D., FACC
Robert C. Robb Jr.
Stem Cell Theranostics and Thermo Fisher Scientific Announce Collaboration to Advance Cardiomyopathy Disease Modeling Workflows
Stem Cell Theranostics Inc
Stem Cell Theranostics secures "freedom to operate" in IP deal with GE Healthcare
Documentaries, videos and podcasts
- Cluster: Stem cell technologyTechnology used for isolating, generating, growing and controlling the differentiation of stem cells into specialized cells and the application of stem cell technology for medical and non-medical purposes such as producing meat through cellular agriculture.
- Cluster: BiotechnologyA cluster of topics related to biotechnology.
- Stem cellStem cells are self-renewing cells that have the potential to become multiple different cell types in the body. Stem cells are found in developing embryos. Adult stem cells maintain and repair tissues throughout life. Induced pluripotent stem cells are a type of stem cell derived from adult cells that are reprogrammed in the lab.